Cargando…

Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma

This study aimed to investigate PD-L1 and PD-1 expression in circulating CD20+ cells in diffuse larger B-cell lymphoma (DLBCL) and to evaluate the predictive and diagnostic performance of PD-L1 versus PD-1 expression in circulating CD20+ cells in DLBCL. Percentages of CD20+, PD-L1+CD20+, and PD-1+CD...

Descripción completa

Detalles Bibliográficos
Autor principal:	Saber, Manal Mohamed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884023/ https://www.ncbi.nlm.nih.gov/pubmed/35225873 http://dx.doi.org/10.3390/antib11010015

Ejemplares similares

Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma
por: Saber, Manal Mohamed
Publicado: (2023)

PD-L1 Is Involved in the Development of Non-Hodgkin’s Lymphoma by Mediating Circulating Lymphocyte Apoptosis
por: Saber, Manal Mohamed
Publicado: (2023)

Prognostic Value of PD-L1, PD-1 and CD8A in Canine Diffuse Large B-Cell Lymphoma Detected by RNAscope
por: Aresu, Luca, et al.
Publicado: (2021)

The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas
por: Garcia-Lacarte, Marcos, et al.
Publicado: (2021)

LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients
por: Liu, Ying, et al.
Publicado: (2021)

PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas
por: Xie, Wei, et al.
Publicado: (2022)

Retracted: LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma
por: Fang, Xia, et al.
Publicado: (2017)

The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma
por: Chen, Benjamin J., et al.
Publicado: (2019)

Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma
por: Song, Moo-Kon, et al.
Publicado: (2019)

IGH::CD274 (PD‐L1) rearrangement in diffuse large B cell lymphoma and its therapeutic implication
por: Wu, Xuemei, et al.
Publicado: (2023)

Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma
por: Vajavaara, Heli, et al.
Publicado: (2021)

PD-L1-expressing extranodal diffuse large B-cell lymphoma, NOS with and without PD-L1 3’-UTR structural variations
por: Takahara, Taishi, et al.
Publicado: (2022)

Diagnostic and Prognostic Utility of PD-1 In B Cell Lymphomas
por: Muenst, S., et al.
Publicado: (2010)

Circulating memory PD-1(+)CD8(+) T cells and PD-1(+)CD8(+)T/PD-1(+)CD4(+)T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients
por: Liu, Jiang, et al.
Publicado: (2023)

Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors
por: Song, Doo-Won, et al.
Publicado: (2021)

MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells
por: Zheng, Zhong, et al.
Publicado: (2019)

PD‐1 expression on the surface of peripheral blood CD4(+) T cell and its association with the prognosis of patients with diffuse large B‐cell lymphoma
por: Zhang, Wei, et al.
Publicado: (2016)

PD1 is highly expressed in diffuse large B-cell lymphoma with hepatitis B virus infection
por: Liu, Zhihe, et al.
Publicado: (2017)

Circulating Exhausted PD-1(+)CD39(+) Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade
por: Martinez-Gomez, Carlos, et al.
Publicado: (2022)

Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
por: Zhang, Wei, et al.
Publicado: (2019)

Expression of PD-L1 and YWHAZ in Patients with Diffuse Large B Cell Lymphoma: A Possible Association with the Prognosis of Lymphoma
por: Yan, Shufang, et al.
Publicado: (2022)

Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma
por: Gu, Qianhui, et al.
Publicado: (2021)

Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma
por: Kwon, Hyun Jung, et al.
Publicado: (2018)

Comparison of PD‐L1 detection assays and corresponding significance in evaluation of diffuse large B‐cell lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1
por: Sun, Jing-Ran, et al.
Publicado: (2019)

Clinicopathologic implication of PD-L1 gene alteration in primary adrenal diffuse large B cell lymphoma
por: Lee, Ki Rim, et al.
Publicado: (2022)

Exosomal PD‑L1 promotes the formation of an immunosuppressive microenvironment in gastric diffuse large B‑cell lymphoma
por: Zeng, Hui, et al.
Publicado: (2023)

PD-1(+) IFN-γ(+) subset of CD8(+) T cell in circulation predicts response to anti–PD-1 therapy in NSCLC
por: Chen, Wenxiu, et al.
Publicado: (2023)

Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells
por: Dong, Ling, et al.
Publicado: (2016)

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy
por: Simon, Sylvain, et al.
Publicado: (2020)

Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma
por: Li, Ji-Wei, et al.
Publicado: (2021)

Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets
por: Chu, Fuliang, et al.
Publicado: (2014)

PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications
por: Xing, Wei, et al.
Publicado: (2016)

Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients
por: Fei, Yue, et al.
Publicado: (2020)

Primary CD20‐positive mediastinal diffuse large B‐cell lymphoma
por: Rajabto, Wulyo, et al.
Publicado: (2020)

Clinicopathological analysis of primary intestinal diffuse large B‐cell lymphoma: Prognostic evaluation of CD5, PD‐L1, and Epstein‐Barr virus on tumor cells
por: Ishikawa, Eri, et al.
Publicado: (2018)

Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy
por: Wang, Chunmeng, et al.
Publicado: (2021)

PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro
por: Quan, Lina, et al.
Publicado: (2015)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
por: Wu, Si-Pei, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sfmulb1f2v0q5c3soklbe5oei1